Sarah Daniels

Sarah is one of tranScrip’s key specialists in Pharmacovigilance and clinical safety and was formerly the EU QPPV for Roche. She has over 30 years of industry experience and is a drug development and medical affairs expert in several therapeutic areas including oncology, virology and CNS.

Sarah is a UK registered pharmaceutical physician with diverse pharmaceutical industry experience gained in blue chip companies at both local and global level. She is a seasoned clinical safety physician and has been the clinical safety lead for several successful indication expansion programs in the oncology arena, including breast cancer and Non-Hodgkin’s Lymphoma. She has also provided safety support in various clinical developmental programs including prostate cancer, malignant melanoma, community acquired pneumonia, and more recently Covid-19, women’s health and orphan drug indications.

Whilst she was the EU QPPV at Roche, she successfully led the company through a series of EU Pharmacovigilance Inspections. Before this, she held the joint responsibilities of Head of the UK Drug Safety Centre and Deputy QPPV.

Sarah’s other industry positions include five years as the UK & Ireland Medical Director at ConvaTec (then a division of Bristol-Myers Squibb), and a 10-year tenure with SmithKline Beecham. During this time, she held a variety of roles from Clinical Pharmacologist through to Director of Medical Affairs, covering a wide range of therapeutic areas including virology, oncology, and CNS, and was involved in several successful MAAs and product launches eg Famvir, Kytril, Hycamtin, Seroxat/Paxil and ReQuip.

Prior to joining the industry, Sarah spent several years as an anaesthetist in the UK National Health Service.

Sarah is a Fellow of the Faculty of Pharmaceutical Medicine.